Revision of Consolidated Financial Results For the Fiscal Year Ending December 31, 2016
 

UMN Pharma Inc. revised ‘Consolidated Financial Results For the Fiscal Year Ended December 31, 2016’announced on February 14, 2017 as follows;

Reason：The deferred tax liabilities on the consolidated and non-consolidated balance sheets had not been properly accounted for.

Effects：Loss attributable to owners of parent, previously reported as \14,099,082 thousand, decreased by \43,384 thousand to loss of \14,099,082 thousand, and Non-consolidated net loss, previously reported as \8,348,590 thousand, decreased by \43,384 thousand to loss of \8,344,420 thousand.

The revised figures are underlined on the attached ‘(Revised) Consolidated Financial Results For the Fiscal Year Ended December 31, 2016.’